BioNTech
↗Mainz, Germany
BioNTech is a global next-generation immunotherapy company pioneering novel investigational therapies for cancer and infectious diseases using mRNA and other advanced biotechnology platforms. Founded in 2008, the company has evolved from a research-focused enterprise into a fully integrated biopharmaceutical organization with research, development, manufacturing, and commercial capabilities. BioNTech's primary focus is harnessing the immune system to address diseases with unmet medical needs through its multi-technology innovation engine, which includes computational medicine, AI, and machine learning. The company is known for its COVID-19 vaccine collaboration with Pfizer and is now transitioning to a diversified portfolio emphasizing oncology and immunotherapy.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Immunotherapy, mRNA therapeutics, Cancer vaccines
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$3.5B-$4.2B (TTM: $3.52B, 2024: $2.96B, 2023: $4.15B)
Founded:2008
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$861M raised in private rounds pre-IPO
Investors:Redmile Group, Janus Henderson Investors, Invus, Fidelity Management & Research, MiraeAsset Financial Group, Platinum Asset Management, European Investment Bank, Temasek Holdings, German Federal Ministry of Education and Research
STOCK
Exchange:NASDAQ
Ticker:BNTX
Market Cap:$25.6B
PIPELINE
Stage:Phase 1-3
Lead Drug Stage:Phase 3
Modalities:mRNA therapies, Antibody-drug conjugates (ADCs), Immunomodulators, mRNA vaccines, Next-generation immunomodulators, CAR-T cell therapies
Active Trials:25
Trial Phases:Phase 1: 5 | Phase 2: 10 | Phase 3: 15
FDA Approvals:2
EMA Approvals:2
CORPORATE STRUCTURE
Subsidiaries:BioNTech Innovative Manufacturing Services (IMFS), CureVac (acquired Dec 2025)
Key Partnerships:Pfizer - COVID-19 vaccine co-development and commercialization, Regeneron - Multiple oncology collaborations (BNT111, BNT112), Bristol Myers Squibb - Strategic partnership, University of Pennsylvania - Penn-BioNTech Innovative Therapeutics Seed Fund ($50M)
COMPETITION
Position:Leader
Competitors:Moderna (mRNA vaccines and therapeutics), Regeneron Pharmaceuticals (immuno-oncology, ADCs), Merck & Co (Keytruda, cancer vaccines MSD-mRNA-4157), Pfizer (large pharma partner, also competitor), Roche (immuno-oncology), Astra Zeneca (oncology)
LEADERSHIP
Key Executives:
Uğur Şahin - Chief Executive Officer & Co-Founder
Özlem Türeci - Chief Medical Officer & Co-Founder
Christoph Huber - Co-Founder
Jens Holstein - Chief Financial Officer
Sierk Poetting - Chief Operating Officer
Annemarie Hanekamp - Chief Commercial Officer
Ryan Richardson - Chief Strategy Officer
James Ryan - Chief Legal Officer & Chief Business Officer
Kylie Jimenez - Chief People Officer
Scientific Founders:Uğur Şahin, Özlem Türeci, Christoph Huber
Board Members:Helmut Jeggle (Supervisory Board Chairman, since 2008)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BioNTech and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BioNTech. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.